KalVista Pharmaceuticals, Inc. (KALV) News

KalVista Pharmaceuticals, Inc. (KALV): $16.80

-0.65 (-3.72%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter KALV News Items

KALV News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

KALV News Highlights

  • For KALV, its 30 day story count is now at 2.
  • Over the past 10 days, the trend for KALV's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest KALV News From Around the Web

Below are the latest news stories about KalVista Pharmaceuticals Inc that investors may wish to consider to help them evaluate KALV as an investment opportunity.

10 Pharmaceutical Stocks to Buy According to Timothy Lynch’s Stonepine Capital

In this article, we take a look at the 10 pharmaceutical stocks to buy according to Timothy Lynch’s Stonepine Capital. If you want to skip our detailed analysis of Stonepine Capital’s history, investment philosophy, and hedge fund preference, go directly to 5 Pharmaceutical Stocks to Buy According to Timothy Lynch’s Stonepine Capital. Timothy Lynch is […]

Yahoo | October 14, 2021

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. & SALISBURY, England, October 04, 2021--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted six newly-hired employees inducement options to purchase an aggregate of 40,000 shares of KalVista common stock on October 1, 2021 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Yahoo | October 4, 2021

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today ann…

FinanzNachrichten | September 21, 2021

KalVista Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference

CAMBRIDGE, Mass. & SALISBURY, United Kingdom, September 21, 2021--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 8:40 a.m. ET.

Yahoo | September 21, 2021

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces the Lifting of FDA Clinical Hold for Phase 2 Trial of KVD824

- US Site Initiations Ongoing - - Regulatory Submissions Complete for All Countries Participating in Trial - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company

FinanzNachrichten | September 14, 2021

FDA Lifts Clinical Hold On KalVista's Hereditary Angioedema Trial

The FDA has lifted the clinical hold on KalVista Pharmaceuticals Inc's (NASDAQ: KALV) Phase 2 trial of KVD824 for oral prophylactic treatment of hereditary angioedema (HAE). Related Content: KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary Angioedema Trial With KVD824. "The execution of KOMPLETE, our Phase 2 clinical trial for KVD824 as a potential oral prophylactic therapy for HAE, is expected to accelerate now that we can also proceed at our U.S. trial sites," said Andrew

Yahoo | September 14, 2021

KalVista Pharmaceuticals Announces the Lifting of FDA Clinical Hold for Phase 2 Trial of KVD824

CAMBRIDGE, Mass. & SALISBURY, England, September 14, 2021--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company’s Phase 2 clinical trial of KVD824 for oral prophylactic treatment of hereditary angioedema (HAE).

Yahoo | September 14, 2021

KalVista Pharmaceuticals Reports First Fiscal Quarter Results Wire

KalVista Pharmaceuticals Reports First Fiscal Quarter Results Business Wire

Business Wire | September 13, 2021

KalVista Pharmaceuticals Reports First Fiscal Quarter Results

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2021. We have made excellent progress in the rollout of our Phase 2 KOMPLETE clinical trial for KVD824, said Andrew Crockett, Chief Executive

Business Wire | September 9, 2021

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports First Fiscal Quarter Results

- FDA End-of-Phase 2 Meeting for KVD900 Oral HAE Phase 3 Program Scheduled for This Month - - KVD824 Phase 2 KOMPLETE Clinical Trial Enrolling - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a cl

FinanzNachrichten | September 9, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6296 seconds.